These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39144147)

  • 1. Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
    Ma J; Lin Z; Zhang Y; Ding Y; Tang Q; Qian Y; Jin B; Luo RY; Liao WL; Thyparambil S; Han Z; Chou CJ; Schilling J; Li Q; Zhang M; Lin Y; Ma Y; Sylvester KG; Nagpal S; McElhinney DB; Ling XB; Chen B
    Front Immunol; 2024; 15():1343109. PubMed ID: 39144147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.
    Ma J; Chen K; Ding Y; Li X; Tang Q; Jin B; Luo RY; Thyparambil S; Han Z; Chou CJ; Zhou A; Schilling J; Lin Z; Ma Y; Li Q; Zhang M; Sylvester KG; Nagpal S; McElhinney DB; Ling XB; Chen B
    Front Mol Biosci; 2023; 10():1257079. PubMed ID: 38028545
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebrospinal fluid-based metabolomics to characterize different types of brain tumors.
    Wang FX; Chen K; Huang FQ; Alolga RN; Ma J; Wu ZX; Fan Y; Ma G; Guan M
    J Neurol; 2020 Apr; 267(4):984-993. PubMed ID: 31822990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein biomarker identification in the CSF of patients with CNS lymphoma.
    Roy S; Josephson SA; Fridlyand J; Karch J; Kadoch C; Karrim J; Damon L; Treseler P; Kunwar S; Shuman MA; Jones T; Becker CH; Schulman H; Rubenstein JL
    J Clin Oncol; 2008 Jan; 26(1):96-105. PubMed ID: 18056677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
    Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
    Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry.
    Waldera-Lupa DM; Poschmann G; Kirchgaessler N; Etemad-Parishanzadeh O; Baberg F; Brocksieper M; Seidel S; Kowalski T; Brunn A; Haghikia A; Gold R; Stefanski A; Deckert M; Schlegel U; Stühler K
    Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32610669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
    Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
    Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma.
    Deng Y; Li Q; Sun J; Ma L; Ding Y; Cai Y; Iliuk A; Chen B; Xie Z; Tao WA
    Analyst; 2023 Jul; 148(15):3594-3602. PubMed ID: 37403840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.
    Loser V; Segot A; de Leval L; Bisig B; Brouland JP; Hewer E; Barcena C; Hottinger AF; Pot C
    BMC Neurol; 2024 Jul; 24(1):250. PubMed ID: 39039441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread.
    Spreafico F; Bongarzone I; Pizzamiglio S; Magni R; Taverna E; De Bortoli M; Ciniselli CM; Barzanò E; Biassoni V; Luchini A; Liotta LA; Zhou W; Signore M; Verderio P; Massimino M
    Oncotarget; 2017 Jul; 8(28):46177-46190. PubMed ID: 28526811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
    Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
    Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas.
    Zajdel M; Rymkiewicz G; Sromek M; Cieslikowska M; Swoboda P; Kulinczak M; Goryca K; Bystydzienski Z; Blachnio K; Ostrowska B; Borysiuk A; Druzd-Sitek A; Walewski J; Chechlinska M; Siwicki JK
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An endoscopically proven ventriculitis-type, cyst-like intraventricular primary lymphoma of the central nervous system.
    Park SW; Yoon SH; Cho KG
    Acta Neurochir (Wien); 2006 Sep; 148(9):981-4. PubMed ID: 16791437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Logistic regression modeling of cytokines for cerebrospinal fluid evaluation in primary central nervous system lymphoma.
    Wang D; Wu Y; Ma J; Xu Z; Tao H; Guan Y; Wang J; Chen K; Chen B; Xie J; Jiang H; Guan M
    Clin Chim Acta; 2024 Aug; 562():119879. PubMed ID: 39029646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.